Iva Healthcare posts 35% growth in terms of sales

Iva Healthcare proudly declared 35% profits growth and got new approvals for Teneligliptin 20mg and Metformin Hydrochloride 500mg {SR}. Iva gave credits of success to their new marketing strategy, competent people and network. The company proudly posts 35% growth rates as compared to normal industry’s 14% CAGR in the last quarter.

The company has witnessed strong revenue and performance and is dedicatedly working to tap a new market and penetrate deeper into Indian Territory with its affordable and quality medicines.

The company experienced the healthy performance this year. Iva team is very dedicated to prioritizing new medical innovation with enhanced capabilities and improved efficiency, helping us to realize their marketing strategy, and driving their next phase of growth.

Iva healthcare is working hard to widening its horizons.This graph clearly explains how Ivs healthcare with their best planning and marketing strategy crossed the gross industry growth and recorded 35% growth in sales.

Iva Healthcare Private Limited is an India based company established in 2008. One of the best well-established pharma manufacturers, wholesaler, and traders. Company’s best products are Pharmaceutical Tablets, Azithromycin Tablets that are high-profit making products from an extensive range of products manufactured.

Iva has manufacturing collaboration with the reputed brand Theon Pharmaceutical Pvt., certified by world health organization for good manufacturing practices and international organization for standardization.

The company has made a special place in the market because of the quality medicines, owing to quick results, longer shelf life, and effectiveness.

Iva company keeps growing and constantly producing new, innovative and vigorous pharma products for all age groups to ensure the healthy living.

The company followed the guidelines and all production activities are taken in a clean and safe environment for the pharmacists and other employees. The company is working at their best levels just to ensure products should be harmless for all age groups and ensure quick and instant recovery.

Related Posts

LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

Phase 2 results for LB-102 showed statistically significant reductions in PANSS total score across all doses with onset by week 1 and sustained through study end, alongside low rates of…

Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

After substandard drug manufacturing, the state drug firms are once again under the scanner of the central government for manufacture and sale of unapproved fixed dose combination (FDC) drugs which…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

Stem cell therapy for autism illegal: NMC advisory

Stem cell therapy for autism illegal: NMC advisory

India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise

NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise